Home/NervGen Pharma/Shamim Ruff

SR

Shamim Ruff

Chief Regulatory Affairs Officer

Therapeutic Areas

Neurology Regenerative Medicine

NervGen Pharma Pipeline

Drug	Indication	Phase
NVG-291	Chronic & Subacute Spinal Cord Injury	Phase 1b/2a
NVG-300	Undisclosed Neurodegenerative Indications	Discovery

Leadership Team at NervGen Pharma

Adam Rogers, MD

Chair, President & Chief Executive Officer

Randall Kaye, MD

Chief Medical Advisor & Director

Christine McSherry

SVP, Patient Advocacy and Clinical Affairs

Harold Punnett, DMD

Director & Co-Founder

View full NervGen Pharma profile